CA2626698C - Methode de traitement d'une diarrhee associee a clostridium difficile - Google Patents

Methode de traitement d'une diarrhee associee a clostridium difficile Download PDF

Info

Publication number
CA2626698C
CA2626698C CA2626698A CA2626698A CA2626698C CA 2626698 C CA2626698 C CA 2626698C CA 2626698 A CA2626698 A CA 2626698A CA 2626698 A CA2626698 A CA 2626698A CA 2626698 C CA2626698 C CA 2626698C
Authority
CA
Canada
Prior art keywords
composition
mcc
use according
weight
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2626698A
Other languages
English (en)
Other versions
CA2626698A1 (fr
Inventor
Pamela Sears
Youe-Kong Shue
Starr Louise Miller-Shangle
Robert Brian Walsh
Farah Babakhani
Yu-Hung Chiu
Alex Romero
Sherwood Gorbach
Thomas John Louie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme LLC
Publication of CA2626698A1 publication Critical patent/CA2626698A1/fr
Application granted granted Critical
Publication of CA2626698C publication Critical patent/CA2626698C/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2626698A 2005-10-21 2006-10-23 Methode de traitement d'une diarrhee associee a clostridium difficile Expired - Fee Related CA2626698C (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US72913505P 2005-10-21 2005-10-21
US60/729,135 2005-10-21
US74964105P 2005-12-12 2005-12-12
US60/749,641 2005-12-12
PCT/US2006/041436 WO2007048059A2 (fr) 2005-10-21 2006-10-23 Méthode de traitement d'une diarrhée associée à clostridium difficile

Publications (2)

Publication Number Publication Date
CA2626698A1 CA2626698A1 (fr) 2007-04-26
CA2626698C true CA2626698C (fr) 2015-12-01

Family

ID=37963388

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2626698A Expired - Fee Related CA2626698C (fr) 2005-10-21 2006-10-23 Methode de traitement d'une diarrhee associee a clostridium difficile

Country Status (8)

Country Link
EP (1) EP1940417A4 (fr)
JP (1) JP2009512691A (fr)
KR (1) KR101399621B1 (fr)
CN (2) CN101340919B (fr)
AU (1) AU2006304868B2 (fr)
CA (1) CA2626698C (fr)
HK (1) HK1126410A1 (fr)
WO (1) WO2007048059A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7906489B2 (en) 2004-05-14 2011-03-15 Optimer Pharmaceuticals, Inc. 18-membered macrocycles and analogs thereof
US7378508B2 (en) 2007-01-22 2008-05-27 Optimer Pharmaceuticals, Inc. Polymorphic crystalline forms of tiacumicin B
TWI523654B (zh) 2007-11-27 2016-03-01 默沙東藥廠 抗生素巨環化合物以及其製造及使用之方法
JO3464B1 (ar) 2013-01-15 2020-07-05 Astellas Pharma Europe Ltd التركيبات الخاصة بمركبات التياكوميسين
CN104846044B (zh) * 2014-02-17 2019-02-01 上海医药工业研究院 一种提高非达霉素产量的发酵培养基
CN105237599B (zh) * 2015-10-09 2018-10-02 华北制药集团新药研究开发有限责任公司 闰年霉素a4晶体及其制备方法
CN107714713B (zh) * 2017-10-25 2020-05-26 中山大学 台勾霉素衍生物在制备治疗登革病毒感染引起的相关疾病和/或症状的药物中的应用
CN107970253B (zh) * 2017-10-25 2020-05-26 中山大学 台勾霉素衍生物在制备治疗寨卡病毒感染引起的相关疾病和/或症状的药物中的应用
CN112805367A (zh) * 2018-06-07 2021-05-14 阿尔图根治疗有限公司 用于治疗艰难梭菌的方法和组合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4918174A (en) 1986-09-26 1990-04-17 Abbott Laboratories Tiacumicin compounds
US5583115A (en) * 1995-05-09 1996-12-10 Abbott Laboratories Dialkyltiacumicin compounds
JP2005534332A (ja) * 2002-07-29 2005-11-17 オプティマー ファーマシューティカルズ、インコーポレイテッド チアクマイシン生産
ES2395404T3 (es) * 2004-05-14 2013-02-12 Optimer Pharmaceuticals, Inc. Tratamiento de las enfermedades asociadas al uso de antibióticos
BRPI0519890A2 (pt) * 2005-01-31 2009-03-31 Optimer Pharmaceuticals Inc macrociclos de 18 elementos e seus análogos

Also Published As

Publication number Publication date
KR101399621B1 (ko) 2014-06-18
EP1940417A2 (fr) 2008-07-09
CA2626698A1 (fr) 2007-04-26
EP1940417A4 (fr) 2010-07-07
KR20080064177A (ko) 2008-07-08
CN101340919B (zh) 2011-12-07
HK1126410A1 (en) 2009-09-04
AU2006304868A1 (en) 2007-04-26
AU2006304868B2 (en) 2013-02-21
JP2009512691A (ja) 2009-03-26
WO2007048059A2 (fr) 2007-04-26
CN102503994A (zh) 2012-06-20
CN101340919A (zh) 2009-01-07
WO2007048059A3 (fr) 2007-05-31

Similar Documents

Publication Publication Date Title
CA2626698C (fr) Methode de traitement d'une diarrhee associee a clostridium difficile
US20140107054A1 (en) Method of treating clostridium difficile-associated diarrhea
CN101128114B (zh) 18元环大环化合物及其类似物
EP2305244B1 (fr) Traitement de maladies consecutives a un traitement antibiotique
AU2009308182A1 (en) Biodefenses using triazole-containing macrolides
Bäckström et al. Effect of ceftobiprole on the normal human intestinal microflora
Citron et al. Typing and susceptibility of bacterial isolates from the fidaxomicin (OPT-80) phase II study for C. difficile infection
Raasch Anidulafungin: review of a new echinocandin antifungal agent
KR0145553B1 (ko) 클로스트리듐 디피실레 하리증 및 위막성 대장염의 예방 및 치료용 의약조성물
Yanagihara et al. Susceptibility of Clostridium species isolated in Japan to fidaxomicin and its major metabolite OP-1118
WO2012050826A1 (fr) Procédés de traitement d'infections par clostridium difficile
CN105919995B (zh) 阿扎霉素f在制备治疗特应性皮炎药物中的应用
EP1670496B1 (fr) Preparation contenant un glycopeptide possedant une activite antibiotique amelioree
Nguelefack et al. Phytochemical composition and in vitro effects of the ethyl acetate bark extract of Distemonanthus benthamianus Baillon (Caesalpiniaceae) on Staphylococcus aureus and Streptococcus agalactiae
Alonso et al. Plasma and peritoneal ceftriaxone concentrations after intraperitoneal administration in horses with septic peritonitis
Katara et al. Role of bacteria and fungi in antibiotic production
Aleem et al. Drugs in therapeutic application of dogs and cats
CN111249296A (zh) 一种抗真菌的药物组合物及互动抗真菌活性测定方法
CN114377032A (zh) 一种激活UPR-XBP1u通路的活性物质
JPH1029947A (ja) 生体内毒素型細菌性腸管感染症治療剤
CN103690526A (zh) 一种阿扎霉素f衍生物和维生素k3的抗菌药物组合物

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20171023